Recent clinical trials highlight tau as a new target for Alzheimer’s drugs. Learn what investigational treatments like diranersen mean for cognitive health.
In September 2026, Axios reported that July trial results for Biogen’s investigational tau-targeting therapy showed slower cognitive decline in people with early-stage Alzheimer’s disease. This development highlights growing scientific interest in tau as a new target for emerging dementia treatments.
The medical treatment at the center of this recent news reporting is Biogen’s diranersen. Medical researchers also identify this investigational tau-targeting medication as BIIB080. According to Axios, patients with early-stage Alzheimer’s disease who received the drug experienced slower cognitive decline. These trial participants also reported mild or moderate side effects during the clinical study. This specific safety profile is a key detail for doctors evaluating long-term treatment viability.
Medical outcomes from this trial present a complicated picture that requires careful reading by older adults and their doctors. Reuters reported that the lowest dose of the medication reduced cognitive decline on five of six clinical assessment tools. This lowest-dose group also demonstrated a significant reduction in levels of the disease-linked protein in their systems. These biological markers are critical for researchers studying how this condition progresses in human patients. Favorable changes in these markers suggest the drug interacts with the intended biological targets.
Even with these positive early signals, the phase 2 CELIA study missed its primary dose-response objective. PharmaVoice noted that the trial failed to show greater clinical benefit at higher medication doses. Instead, the lower-dose group demonstrated the strongest result compared with a placebo group. PharmaVoice characterized this clinical outcome as modest overall. This means the drug did not behave exactly as researchers hypothesized at higher concentrations.
While the trial missed its primary objective, the medical community found some value in the data. The Alzheimer’s Association called the findings a signal that gives the field reason for optimism, according to Axios. This reaction reflects a broader pharmaceutical shift toward investigating multiple pathways of disease progression. It shows that experts value incremental progress in understanding how to target tau effectively.
Currently available anti-amyloid medications have shown modest success in slowing progression in patients with mild cognitive impairment. Axios named lecanemab, marketed as Leqembi by Eisai and Biogen, and Eli Lilly’s Kisunla among these approved drugs. However, Axios reported that their clinical benefits remain limited in real-world practice. These existing treatments also carry significant safety concerns like brain swelling and bleeding.
These specific safety issues directly influence how physicians view new medical treatment options. A TD Cowen survey cited by Axios found that 88% of doctors said they were likely or very likely to use an effective therapy requiring less monitoring. The medical community is actively looking for treatments that are easier to manage safely in standard clinical practice. Doctors prefer medications that do not require intense or continuous observation for severe side effects.
Because of the limitations associated with current anti-amyloid drugs, the physician community considers tau a highly relevant focus for intervention. In the same TD Cowen survey, 84% of doctors indicated they were likely or very likely to prescribe a tau therapy alongside an anti-amyloid treatment. Researchers are increasingly considering combination strategies that pair amyloid-removing drugs with tau-suppressing therapies. Axios noted this approach could possibly occur alongside medications that address brain inflammation.
Clinical trials are already testing these specific combination approaches in human patients today. A UCSF Alzheimer’s Tau Platform trial is actively evaluating tau-directed therapies in adults aged 50 to 80. This study involves individuals with late preclinical or early prodromal Alzheimer’s disease. UCSF designed this trial to test tau treatments alone or in combination with donanemab. Evaluating these drugs together helps scientists understand if treating multiple disease mechanisms simultaneously provides better outcomes.
While early trial signals generate significant media attention, readers must separate investigational research from available medical care. Axios reported that the FDA had not approved any tau therapies at the time of publication. Diranersen remains an experimental drug in clinical trials rather than a current treatment option for consumers. Furthermore, these studies involve people with early-stage disease rather than serving as a general prevention strategy for cognitively healthy older adults.
Financial projections can also create a false sense of certainty about unproven clinical treatments. Axios highlighted a TD Cowen analysis estimating the market for next-generation Alzheimer’s treatments could reach $70 billion within a decade. This massive figure rests on several specific demographic and financial assumptions. The analysis considered an eligible group of 3.8 million people with mild cognitive impairment. This estimated group represents a large potential patient base for future pharmaceutical products.
To reach that expected market size, the TD Cowen analysis assumed three-quarters of these individuals would take a treatment priced at $20,000 a year. Based on these precise figures, the report projected a $60 billion market that could grow to $70 billion by 2035. These numbers are purely analyst forecasts about future spending. They are not guaranteed market outcomes or confirmed public health solutions for older adults.
Additionally, a high volume of ongoing research does not guarantee clinical success or actual patient benefit. A 2026 pipeline review reported 158 drugs across 192 active trials. Axios similarly cited 158 drugs in development, spanning disease-modifying treatments and symptom management therapies. A large pharmaceutical pipeline shows active scientific effort, but it does not mean that most of these drugs will prove effective. Many experimental treatments fail to show sufficient safety or benefit in later testing phases.
Before these emerging therapies reach mainstream clinical use, drug developers must resolve several significant scientific challenges. Axios highlighted outstanding scientific questions regarding whether doctors can remove tau safely from the brain. Researchers must also figure out the most effective ways to deliver these medications across the blood-brain barrier. These physiological hurdles require years of rigorous clinical testing to overcome safely.
Even if scientists clear these clinical hurdles, access and financial affordability will remain pressing public health concerns. Axios pointed out that it is still unclear whether Medicare or commercial insurers would cover a future tau treatment. The long timeline of clinical testing means widespread availability is likely a distant prospect. Trials like the UCSF platform will need significant time to gather conclusive medical data before seeking regulatory review.
The ongoing research into diranersen and other tau-targeting drugs marks a shift in how science approaches cognitive health. TD Cowen managing director and senior research analyst Joseph Thome told Axios that physicians regard tau as a highly active clinical target. He noted that slowing disease progression by 25% to 30% is the bar for new treatments. While the current findings missed certain study objectives, they validate the medical strategy of targeting multiple mechanisms of brain aging.
As pharmaceutical companies continue their clinical trials, the treatment landscape for older adults will likely grow more complex. The potential for combination therapies offers a realistic path forward rather than an immediate cure. Keeping up with these medical developments requires careful attention to what clinical research actually proves. For adults focusing on memory and cognition, separating established facts from early scientific signals remains the safest approach.
Older adults and their personal doctors are often left to manage uncertainty about which everyday habits may support cognitive health. Consulting FitBrainLab changes this dynamic by delivering clear, research-led editorial guidance on brain aging and neuroplasticity. This direct translation of complex medical evidence helps you make informed choices without fear or exaggerated claims. Explore Resources
Follow FitBrainLab for research-led insights on memory, focus, brain aging, nutrition and mental fitness after 60. Stay connected for new articles, practical guidance and ideas for a sharper, more engaged life.
Build habits that support memory, focus and a curious, connected life.
Read the Blog
